The impact of hepatitis B core antibody levels on HBV reactivation after allogeneic hematopoietic SCT: an 11-year experience at a single center.
The Center for Liver Disease, Hamanomachi Hospital, Fukuoka, Japan.
S K
SK
Bae
The Center for Liver Disease, Hamanomachi Hospital, Fukuoka, Japan.
T
T
Gushima
Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan.
N
N
Saito
Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan.
I
I
Yamanaka
Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan.
T
T
Shimokawa
Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan.
Y
Y
Matsuo
Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan.
S
S
Yoshida
Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan.
I
I
Kawano
Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan.
H
H
Henzan
Medicine and Biosystemic Science, Kyushu University, Fukuoka, Japan.
S
S
Shimoda
Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan.
T
T
Eto
The Center for Liver Disease, Hamanomachi Hospital, Fukuoka, Japan.
K
K
Takahashi
D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006510:Hepatitis B Antibodies / Q000097:blood*; D006515:Hepatitis B virus / Q000502:physiology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012307:Risk Factors; D014184:Transplantation, Homologous; D014775:Virus Activation
D000998:Antiviral Agents; D006510:Hepatitis B Antibodies